

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Casdin Partners Master Fund, L.P.</u>  (Last) (First) (Middle) 1350 AVENUE OF THE AMERICAS SUITE 2600  (Street) NEW YORK NY 10019  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>STANDARD BIOTOOLS INC. [ LAB ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 01/05/2024	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
Rule 10b5-1(c) Transaction Indication  <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/05/2024		A		11,246,525	A	(1)	11,246,525	D(1)	
Common Stock	01/05/2024		A		2,744,219	A	(2)	2,744,219	I	See footnote(2)
Common Stock								1,200,000	I	See footnote(3)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person\*  
Casdin Partners Master Fund, L.P.  
 (Last) (First) (Middle)  
 1350 AVENUE OF THE AMERICAS  
 SUITE 2600  
 (Street)  
 NEW YORK NY 10019  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Casdin Capital, LLC  
 (Last) (First) (Middle)  
 1350 AVENUE OF THE AMERICAS  
 SUITE 2600  
 (Street)  
 NEW YORK NY 10019  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*

[Casdin Partners GP, LLC](#)

(Last) (First) (Middle)

1350 AVENUE OF THE AMERICAS  
SUITE 2600

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person<sup>†</sup>

[Casdin Private Growth Equity Fund II, L.P.](#)

(Last) (First) (Middle)

1350 AVENUE OF THE AMERICAS  
SUITE 2600

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person<sup>†</sup>

[Casdin Private Growth Equity Fund II GP, LLC](#)

(Last) (First) (Middle)

1350 AVENUE OF THE AMERICAS, SUITE 2600

(Street)

(City) (State) (Zip)

1. Name and Address of Reporting Person<sup>†</sup>

[Casdin Private Growth Equity Fund, L.P.](#)

(Last) (First) (Middle)

1350 AVENUE OF THE AMERICAS  
SUITE 2600

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person<sup>†</sup>

[CASDIN PRIVATE GROWTH EQUITY  
FUND GP, LLC](#)

(Last) (First) (Middle)

1350 AVENUE OF THE AMERICAS  
SUITE 2600

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person<sup>†</sup>

[Casdin Partners FO1-MSV, LP](#)

(Last) (First) (Middle)

C/O CASDIN PARTNERS GP, LLC  
1350 AVENUE OF THE AMERICAS, SUITE 2600

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

**Explanation of Responses:**

1. Received in exchange for 10,132,005 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Company's common stock (the "Exchange Ratio") at the effective time of the Merger (the "Effective Time"). The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
2. Received in exchange for 2,472,270 shares of common stock of SomaLogic pursuant to the Merger. Per the terms of the Merger, each share of SomaLogic common stock was converted pursuant to the Exchange Ratio at the Effective Time. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
3. The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

**Remarks:**

Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer. By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the Reporting Persons may be deemed directors by deputization of the Issuer. Mr. Casdin files separate Section 16 reports disclosing securities of the Issuer that he may be deemed to beneficially own for Section 16 purposes. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Casdin Partners Master Fund,  
LP By: Casdin Partners GP,  
LLC, its General Partner By: 01/09/2024  
/s/ Eli Casdin, Managing  
Member  
Casdin Capital LLC By: /s/ Eli 01/09/2024  
Casdin, Managing Member  
Casdin Partners GP LLC By:  
/s/ Eli Casdin, Managing 01/09/2024  
Member  
Casdin Private Growth Equity  
Fund II, L.P. By: Casdin  
Private Growth Equity Fund II  
GP, LLC, its General Partner 01/09/2024  
By: /s/ Eli Casdin, Managing  
Member  
Casdin Private Growth Equity  
Fund GP II, LLC By: /s/ Eli 01/09/2024  
Casdin, Managing Member  
Casdin Private Growth Equity  
Fund, L.P., By: Casdin Private  
Growth Equity Fund II GP,  
LLC, its General Partner, By: 01/09/2024  
/s/ Eli Casdin, Managing  
Member  
Casdin Private Growth Equity  
Fund GP, LLC, By: /s/ Eli 01/09/2024  
Casdin, Managing Member, /s/  
Eli Casdin, Eli Casdin  
Casdin Partners FO1-MSV, LP  
By: Casdin Partners GP, LLC,  
its General Partner By: /s/ Eli 01/09/2024  
Casdin, Managing Member  
\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**